Future anticoagulants in interventional cardiology: Anti-IXa and anti-Xa agents in percutaneous coronary intervention

Future Cardiology

Volumn 7, Issue 3, 2011, Pages 281-285

  Lombo, Bernardo ^a   Díez, José G ^b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

anticoagulation; aptamers; fondaparinux; heparin; otamixaban; percutaneous coronary intervention

Indexed keywords

ANTIBODY; ANTICOAGULANT AGENT; ANTITHROMBIN; APTAMER; BLOOD CLOTTING FACTOR 10A ANTIBODY; BLOOD CLOTTING FACTOR 10A INHIBITOR; FIBRINOGEN RECEPTOR ANTAGONIST; FONDAPARINUX; HEPARIN; OTAMAXIBAN; UNCLASSIFIED DRUG;

ACUTE CORONARY SYNDROME; DRUG MECHANISM; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; REVIEW;

ANGIOPLASTY, BALLOON, CORONARY; ANTICOAGULANTS; CORONARY ARTERY DISEASE; CYCLIC N-OXIDES; FACTOR IXA; HEPARIN; HIRUDINS; HUMANS; PEPTIDE FRAGMENTS; POLYSACCHARIDES; PYRIDINES; RECOMBINANT PROTEINS;

EID: 79958101790     PISSN: 14796678     EISSN: 17448298     Source Type: Journal    
DOI: 10.2217/fca.11.20     Document Type: Review

References (17)

1. Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J. Am. Coll. Cardiol. 50(7), e1-e157 (2007).
2. Bassand JP, Hamm CW, Ardissino D, et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur. Heart J. 28(13), 1598-1660 (2007).
3. Schiele F: Fondaparinux and acute coronary syndromes: update on the OASIS 5-6 studies. Vasc. Health Risk Manag. 6, 179-187 (2010).
4. Turpie AG, Gallus AS, Hoek JA: A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement. N. Engl. J. Med. 344(9), 619-625 (2001). (Pubitemid 32183576)
5. Turpie AG: Fondaparinux in the management of patients with ST-elevation acute myocardial infarction. Vasc. Health Risk Manag. 2(4), 371-378 (2006). (Pubitemid 46231269)
6. Yusuf S, Mehta SR, Chrolavicius S, et al. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N. Engl. J. Med. 354(14), 1464-1476 (2006).
7. Yusuf S, Mehta SR, Chrolavicius S, et al. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. JAMA 295(13), 1519-1530 (2006).
8. Mehta SR: Clinical benefit and practical use of fondaparinux in the invasive management of patients with acute coronary syndromes. Eur. Heart J. Suppl. 10, 14-21 (2008).
9. Budaj A, Eikelboom JW, Mehta SR, et al. Improving clinical outcomes by reducing bleeding in patients with non-ST-elevation acute coronary syndromes. Eur. Heart J. 30(6), 655-661 (2009).
10. Wienbergen H, Zeymer U: Management of acute coronary syndromes with fondaparinux. Vasc. Health Risk Manag. 3(3), 321-329 (2007). (Pubitemid 47214975)
11. Mehta SR, Boden WE, Eikelboom JW, et al. Antithrombotic therapy with fondaparinux in relation to interventional management strategy in patients with ST- and non-ST-segment elevation acute coronary syndromes: an individual patient-level combined analysis of the Fifth and Sixth Organization to Assess Strategies in Ischemic Syndromes (OASIS 5 and 6) randomized trials. Circulation 118(20), 2038-2046 (2008).
12. Stief TW: Kallikrein activates prothrombin. Clin. Appl. Thromb. Hemost. 14(1), 97-98 (2008).
13. Steg PG, Jolly SS, Mehta SR, et al. Low-dose vs standard-dose unfractionated heparin for percutaneous coronary intervention in acute coronary syndromes treated with fondaparinux: the FUTURA/OASIS-8 randomized trial. JAMA 304(12), 1339-1349 (2010).
14. Cohen M, Bhatt DL, Alexander JH, et al. Randomized, double-blind, dose-ranging study of otamixaban, a novel, parenteral, short-acting direct factor Xa inhibitor, in percutaneous coronary intervention: the SEPIA-PCI trial. Circulation 115(20), 2642-2651 (2007). (Pubitemid 46791363)
15. Sabatine MS, Antman EM, Widimsky P, et al. Otamixaban for the treatment of patients with non-ST-elevation acute coronary syndromes (SEPIA-ACS1 TIMI 42), a randomised, double-blind, active-controlled, Phase 2 trial. Lancet 374(9692), 787-795 (2009).
16. Becker RC, Povsic T, Cohen MG, Rusconi CP, Sullenger B: Nucleic acid aptamers as antithrombotic agents: opportunities in extracellular therapeutics. Thromb. Haemost. 103, 586-595 (2010).
17. Duke Clinical Research Institute: Primary results of the RADAR randomized clinical trial www.dcri.org/education-training/meetings/meeting-presentations/ acc-2011- presentations/RADAR%20ACC11%20 LBCT%20040311%20Public.pptx/view (Accessed 4 May 2011)